EUVIMEDEUVIMED entdecken
Crossref

Association between Sarcopenia and Anthracycline-Induced Cardiotoxicity in Patients with Cancer

Azin Alizadehasl, Mehran Gheshlaghi, Mahsa Masjedi Esfahani, Sina Sadati, Hosein Sheibani, Bahram Mohebbi, Farzaneh Ashrafi, Maryam Honardoost, Mohammad Faranoush, Mohammad Sadegh Keshmiri, Seyedeh Fatemeh Hosseini Jebelli, Seyedeh Leila Emadian Razavi

Research in Heart Yield and Translational Medicine (RHYTHM) · 28.10.2026

DOI: 10.18502/rhythm.v21i4.23092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research in Heart Yield and Translational Medicine (RHYTHM), online erschienen am 28.10.2026. Verfasst von Azin Alizadehasl und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anthracycline-based chemotherapy is associated with cancer therapy–related cardiac dysfunction, primarily manifested by a decline in left ventricular ejection fraction (LVEF). Sarcopenia, characterized by reduced skeletal muscle mass and strength, shares mechanistic pathways with anthracycline cardiotoxicity, including mitochondrial dysfunction, oxidative stress, and systemic inflammation. We aimed to investigate the association between postchemotherapy sarcopenia and changes in cardiac function in a heterogeneous cohort of patients with cancer.

Methods

In this single-center prospective observational study, 163 adult patients scheduled to receive anthracycline-containing chemotherapy were enrolled. Transthoracic echocardiography was performed before treatment and 3 months after completion, with assessment of LVEF using the biplane Simpson method and global longitudinal strain. Sarcopenia was assessed postchemotherapy using computed tomography–derived skeletal muscle index at the L3 level combined with handgrip strength. Cardiotoxicity was defined as a reduction in LVEF of 10% or more to below normal and/or new diastolic dysfunction. Multivariable logistic regression was used to evaluate independent associations.

Results

Sarcopenia was identified in 46% of patients following chemotherapy. Significant differences in echocardiographic outcomes were observed between sarcopenic and nonsarcopenic groups (P

Zitieren

APA

Alizadehasl, A., Gheshlaghi, M., Esfahani, M. M., Sadati, S., Sheibani, H., Mohebbi, B., Ashrafi, F., Honardoost, M., Faranoush, M., Keshmiri, M. S., Jebelli, S. F. H., & Razavi, S. L. E. (2026). Association between Sarcopenia and Anthracycline-Induced Cardiotoxicity in Patients with Cancer. Research in Heart Yield and Translational Medicine (RHYTHM). https://doi.org/10.18502/rhythm.v21i4.23092

Vancouver

Alizadehasl A, Gheshlaghi M, Esfahani MM, Sadati S, Sheibani H, Mohebbi B, et al. Association between Sarcopenia and Anthracycline-Induced Cardiotoxicity in Patients with Cancer. Research in Heart Yield and Translational Medicine (RHYTHM). 2026. doi:10.18502/rhythm.v21i4.23092

BibTeX
@article{Alizadehasl2026,
  author = {Alizadehasl, Azin and Gheshlaghi, Mehran and Esfahani, Mahsa Masjedi and Sadati, Sina and Sheibani, Hosein and Mohebbi, Bahram and Ashrafi, Farzaneh and Honardoost, Maryam and Faranoush, Mohammad and Keshmiri, Mohammad Sadegh and Jebelli, Seyedeh Fatemeh Hosseini and Razavi, Seyedeh Leila Emadian},
  title = {Association between Sarcopenia and Anthracycline-Induced Cardiotoxicity in Patients with Cancer},
  journal = {Research in Heart Yield and Translational Medicine (RHYTHM)},
  year = {2026},
  doi = {10.18502/rhythm.v21i4.23092}
}
Kostenlos starten →